Olipudase alfa (Xenpozyme®) is a recombinant human ASM enzyme replacement therapy (ERT) approved for the treatment of the non-central nervous system (CNS) manifestations of ASMD in children and adults. The gene discussed is SMPD1; the disease is anterior segment dysgenesis.